[Antihypertensive treatment and risk of coronary disease. How significant is the antihypertensive effect for metabolic factors?].
A recent meta-analysis of hypertension treatment trials showed a marked reduction in cerebrovascular disease and a less pronounced reduction in coronary heart disease. Treatment has consisted of diuretics and betablockers, and this paper discusses the possible influence of their metabolic side effects as compared with the new vasodilating agents (angiotensin converting enzyme inhibitors, alpha receptor antagonists and calcium channel blockers). Several studies have now been started to compare the effect of these compounds with diuretics and betablockers with respect to long-term cardiovascular morbidity and mortality. Until the results of these studies are available, young patients (i.e. < 60-65 years) at high risk of coronary heart disease, especially patients with the insulin resistance syndrome or diabetes mellitus, should in our opinion be treated with ACE-inhibitors, alpha receptor blockers or calcium channel blockers.
Moan
A
A
Medisinsk Klinikk, Ullevål sykehus, Oslo.
Os
I
I
Hjermann
I
I
Kjeldsen
S E
SE
D000367:Age Factors; D000959:Antihypertensive Agents / Q000009:adverse effects*; D001786:Blood Glucose / Q000032:analysis; D003327:Coronary Disease / Q000139:chemically induced*; D005260:Female; D006801:Humans; D007333:Insulin Resistance; D008055:Lipids / Q000097:blood; D008297:Male; D008875:Middle Aged; D012307:Risk Factors
D000959:Antihypertensive Agents; D001786:Blood Glucose; D008055:Lipids
Blodtrykksbehandling og risiko for koronar hjertesykdom. Hvilken betydning har antihypertensivers virkning på metabolske faktorer?